Skip to main content
| News

Lonza manufactures coronavirus vaccine for Moderna

17.11.2020

Lonza plans to start production of Moderna’s coronavirus vaccine in Switzerland before the end of the year. Moderna published the initial results from a phase 3 study, according to which the vaccine candidate is 94.5 percent effective. Moderna opened a subsidiary in Basel to drive forward the production of the vaccine from there.

Moderna is a vaccine manufacturer working on a COVID-19 vaccine. Based in Massachusetts, the manufacturer has founded a subsidiary in Basel. According to Basel Area Business & Innovation in August, Moderna was “vigorously supported” when setting up the new company, Moderna Switzerland GmbH. The support ranged from questions on setting up a company and work permits with regard to the COVID-19 situation to suggestions about office spaces. The successful establishment of a subsidiary by Moderna will highlight the attractiveness of the Basel area’s biotech ecosystem.

Lonza will manufacture the mRNA-1273 vaccine for Moderna. According to a press release from the Basel-based pharmaceutical supplier, large-scale production started at its American factory in Portsmouth, NH at the end of September. Production is also set to start at Lonza’s factory in Visp in the canton of Wallis before the end of the year. Lonza plans to manufacture 400 million vaccine doses per year at Visp. Back in May, Moderna and Lonza agreed on a total manufacturing output of 1 billion doses per year.

Moderna has recently published the initial results from a phase 3 study, according to which the vaccine candidate is 94.5 percent effective.

Lonza is also working on the development of a coronavirus vaccine with another American manufacturer: Humanigen. Cameron Durrant, CEO of Humanigen, is quoted in a press release on the collaboration, saying: “This collaboration with Lonza, a global manufacturing leader with expertise in technology transfer and an established track record of working with regulatory bodies for approved and commercialized products, comes at a crucial time to meet production demand for COVID-19 therapeutics this winter.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Invest

How Moderna is growing in Switzerland

The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sandoz decides on Basel for headquarters

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...

Read More
VectivBio sold for approximately 1 billion dollars
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest

Rami Swiss and Elbit Systems now manufacturing in Jura

The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel to become Europe’s Silicon Valley of biotech

Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....

Read More
1 2 3 63

Do you have a question? We'd like to hear from you.